Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A ...

Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...

Superluminal growing his stocks After Superluminal won the 2015 Jamaica St Leger over 2,000 metres, beating current Horse of the Year Seeking My Dream by a length, he did not progress as expected.

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...